Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $611.51M.
ENTERPRISE VALUE (EV)
$611.51M
4D Molecular Therapeutics, Inc.
Market Cap
$671.75M
Enterprise Value (EV)
$611.51M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $671.75M | $611.51M |
| Helus Pharma Inc. (HELP)vs › | $671.42M | $505.25M |
| Annexon, Inc. (ANNX)vs › | $669.30M | $494.68M |
| MiMedx Group, Inc. (MDXG)vs › | $668.98M | $534.64M |
| ArriVent BioPharma, Inc. (AVBP)vs › | $680.46M | $526.13M |
| Solid Biosciences Inc. (SLDB)vs › | $683.73M | $544.49M |
| Starling Oncology, Inc. (STLN)vs › | $656.15M | $719.53M |
| Verastem, Inc. (VSTM)vs › | $685.85M | $633.83M |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $697.47M | $649.53M |
| Anteris Technologies Global Corp. (AVR)vs › | $698.13M | $444.06M |
Market Cap
$671.75M
Total Debt
$0.00
Cash
$60.24M
Enterprise Value
$611.51M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
